Expression of YY1 in Wilms Tumors with Favorable Histology is a Risk Factor for Adverse Outcomes

Zapata‐Tarrés, Marta; Juárez-Villegas, Luis Enrique; Maldonado-Valenzuela, Altagracia; Baay-Guzmán, Guillermina; Lopez-Perez, Tania V.; Cabrera-Muñoz, Lourdes; Sadowinski-Pine, Stanislaw; Huerta-Yépez, Sara

doi:10.2217/fon-2018-0764

Cited by 13 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Marta et al reported that YY1 expression was higher in the blastemal component of tumors, and high nuclear expression positively correlated with metastasis. YY1 may be considered as a metastasis risk factor in WT 19 . Hontecillas‐Prieto et al suggested that HMGA2 plays a prominent role in the pathogenesis of the blastemal WT subtype, and is heavily connected with relapse and chemotherapy resistance 20 .…”

Section: Discussionmentioning

confidence: 99%

The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China

Huang

Zhen

Lü

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

This study aimed to retrospectively analyze survival outcomes for Chinese patients with prechemotherapy blastemal predominant histology type Wilms tumors (WTs). Methods: We collected and analyzed clinical data concerning patients aged <15 years with favorable histology (FH) WTs treated at the Sun Yat-Sen University Cancer Center from December 2005 to May 2016, based on the Children's Oncology Group protocol. Pathological specimens were collected through biopsy or surgical resection before initiation of chemotherapy. We analyzed survival outcomes involving different prechemotherapy histology subtypes. Results: We enrolled 97 patients with FH WTs (median follow-up, 71.5 months; range, 22.2-170.7). The total recurrence rate was 17.5%, and the subtype recurrence rates were as follows: blastemal predominant (45.5%), mixed (7.5%), epithelial (14.3%), and mesenchymal (9.5%) (P = .010). Five-year event-free survival (EFS) and overall survival (OS) rates were 84.9% and 81.4%, respectively. Respective 5-year EFS and OS rates for subtypes were as follows: blastemal predominant (54.5% and 68.2%), mixed (90.0% and 88.9%), epithelial (85.7% and 85.1%), and mesenchymal (90.5% and 94.7%). Multivariate survival analyses showed that the blastemal predominant subtype was an independent prognostic factor of EFS (P = .001) and OS (P = .017). Conclusions: Our findings showed that prechemotherapy blastemal predominant WTs had higher recurrence and lower EFS and OS rates. Our findings suggested that, albeit with some deficiencies, blastemal predominant histology WT-diagnosed prechemotherapy may have prognostic relevance. Further research into other

show abstract

Section: Discussionmentioning

confidence: 99%

The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China

Huang

Zhen

Lü

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…The IHC of all the biomarkers analyzed in this study were performed as previously described ( Zapata-Tarres et al, 2019 ). Briefly, serial sections of the breast TMA were deparaffinized with xylene, and then rehydrated with graded ethanol.…”

Section: Methodsmentioning

confidence: 99%

“…Immunohistochemically stained samples were analyzed as previously described ( Zapata-Tarres et al, 2019 ). Briefly, immunostained sections for each protein were digitized at a 40x magnification using an Aperio ScanScope CS (Leica BioSystems.…”

Section: Methodsmentioning

confidence: 99%

p21-Activated Kinase 1 Promotes Breast Tumorigenesis via Phosphorylation and Activation of the Calcium/Calmodulin-Dependent Protein Kinase II

Saldívar-Cerón

Villamar-Cruz

Wells

et al. 2022

Front. Cell Dev. Biol.

Self Cite

View full text Add to dashboard Cite

p21-Activated kinase-1 (Pak1) is frequently overexpressed and/or amplified in human breast cancer and is necessary for transformation of mammary epithelial cells. Here, we show that Pak1 interacts with and phosphorylates the Calcium/Calmodulin-dependent Protein Kinase II (CaMKII), and that pharmacological inhibition or depletion of Pak1 leads to diminished activity of CaMKII. We found a strong correlation between Pak1 and CaMKII expression in human breast cancer samples, and combined inhibition of Pak1 and CaMKII with small-molecule inhibitors was synergistic and induced apoptosis more potently in Her2 positive and triple negative breast cancer (TNBC) cells. Co-adminstration of Pak and CaMKII small-molecule inhibitors resulted in a dramatic reduction of proliferation and an increase in apoptosis in a 3D cell culture setting, as well as an impairment in migration and invasion of TNBC cells. Finally, mice bearing xenografts of TNBC cells showed a significant delay in tumor growth when treated with small-molecule inhibitors of Pak and CaMKII. These data delineate a signaling pathway from Pak1 to CaMKII that is required for efficient proliferation, migration and invasion of mammary epithelial cells, and suggest new therapeutic strategies in breast cancer.

show abstract

“…All the lung tissue sections were circumscribed and sent for automated image analysis using Spectrum Software version 11.1.2.752 (Aperio). For immunostaining GC intensity quantification, an algorithm was developed to determine the total lung expression of cortisone and corticosterone in the whole tissue section (26)(27)(28).…”

Section: Preparation Of Lung Tissue For Histological and Immunohistochemistry Analysismentioning

confidence: 99%

16α-Bromoepiandrosterone as a new candidate for experimental diabetes–tuberculosis co-morbidity treatment

López-Torres

Marquina‐Castillo

Ramos-Espinosa

et al. 2021

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Tuberculosis (TB) is the leading cause of death from a single bacterial infectious agent and is one of the most relevant issues of public health. Another pandemic disease is type II diabetes mellitus (T2D) that is estimated to affect half a billion people in the world. T2D is directly associated with obesity and a sedentary lifestyle and is frequently associated with immunosuppression. Immune dysfunction induced by hyperglycemia increases infection frequency and severity. Thus, in developing countries the T2D/TB co-morbidity is frequent and represents one of the most significant challenges for the health-care systems. Several immunoendocrine abnormalities are occurring during the chronic phase of both diseases, such as high extra-adrenal production of active glucocorticoids (GCs) by the activity of 11-β-hydroxysteroid dehydrogenase type 1 (11-βHSD1).11-βHSD1 catalyzes the conversion of inactive cortisone to active cortisol or corticosterone in lungs and liver, while 11-β-hydroxysteroid dehydrogenase type 2 (11-βHSD2) has the opposite effect. Active GCs have been related to insulin resistance and suppression of Th1 responses, which are deleterious factors in both T2D and TB. The anabolic adrenal hormone dehydroepiandrosterone (DHEA) exerts antagonistic effects on GC signaling in immune cells and metabolic tissues; however, its anabolic effects prohibit its use to treat immunoendocrine diseases. 16α-bromoepiandrosterone (BEA) is a water miscible synthetic sterol related to DHEA that lacks an anabolic effect while amplifying the immune and metabolic properties with important potential therapeutic uses. In this work, we compared the expression of 11-βHSD1 and the therapeutic efficacy of BEA in diabetic mice infected with tuberculosis (TB) (T2D/TB) with respect to non-diabetic TB-infected mice (TB). T2D was induced by feeding mice with a high-fat diet and administering a single low-dose of streptozotocin. After 4 weeks of T2D establishment, mice were infected intratracheally with a high-dose of Mycobacterium tuberculosis strain H37Rv.Then, mice were treated with BEA three times a week by subcutaneous and intratracheal routes. Infection with TB increased the expression of 11-βHSD1 and corticosterone in the lungs and liver of both T2D/TB and TB mice; however, T2D/TB mice developed a more severe lung disease than TB mice. In comparison with untreated animals, BEA decreased GC and 11-βHSD1 expression while increasing 11-βHSD2 expression. These molecular | 233

show abstract

Expression of YY1 in Wilms Tumors with Favorable Histology is a Risk Factor for Adverse Outcomes

Cited by 13 publications

References 32 publications

The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China

The prognosis of prechemotherapy blastemal predominant histology subtype in Wilms tumor: A retrospective study in China

p21-Activated Kinase 1 Promotes Breast Tumorigenesis via Phosphorylation and Activation of the Calcium/Calmodulin-Dependent Protein Kinase II

16α-Bromoepiandrosterone as a new candidate for experimental diabetes–tuberculosis co-morbidity treatment

Contact Info

Product

Resources

About